Boston Scientific Co. (NYSE:BSX) Shares Sold by FIL Ltd

FIL Ltd decreased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,895,561 shares of the medical equipment provider's stock after selling 424,779 shares during the period. FIL Ltd owned 0.54% of Boston Scientific worth $705,232,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of BSX. Norges Bank acquired a new stake in Boston Scientific in the 4th quarter worth approximately $1,762,522,000. Wellington Management Group LLP raised its stake in Boston Scientific by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after acquiring an additional 3,344,571 shares during the last quarter. Axiom Investors LLC DE lifted its position in Boston Scientific by 208.2% during the 4th quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after acquiring an additional 2,535,007 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Boston Scientific in the fourth quarter valued at about $190,780,000. Finally, Invesco Ltd. raised its stake in shares of Boston Scientific by 13.6% in the fourth quarter. Invesco Ltd. now owns 15,790,666 shares of the medical equipment provider's stock worth $1,410,422,000 after purchasing an additional 1,893,012 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research report on Monday, March 3rd. UBS Group raised their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Morgan Stanley lifted their price objective on Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Finally, Raymond James lifted their price target on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $109.04.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the transaction, the chief financial officer now directly owns 225,808 shares of the company's stock, valued at $23,764,033.92. The trade was a 22.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 133,183 shares of company stock worth $13,948,476 over the last three months. Insiders own 0.50% of the company's stock.

Boston Scientific Trading Up 1.1 %

NYSE:BSX traded up $1.02 on Friday, hitting $93.66. The stock had a trading volume of 8,303,541 shares, compared to its average volume of 6,356,881. The company has a fifty day moving average price of $100.54 and a two-hundred day moving average price of $94.10. The stock has a market cap of $138.53 billion, a price-to-earnings ratio of 74.93, a PEG ratio of 2.79 and a beta of 0.73. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.